EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Identification of Pyrazolidine‐3‐One Derivatives as a Novel Structural Scaffold for ATP Synthase Inhibitors

Lisa Reichert, Aro Delparente, Ida R Hipfinger, Lukas Reininger, Ana Pinto Castro, Daniel J Hubin, Roger Schibli, Amy E Fraley iD, Linjing Mu

ChemMedChem · 29.07.2026 · 21 (14)

DOI: 10.1002/cmdc.70399 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemMedChem, online erschienen am 27.07.2026. Verfasst von Lisa Reichert und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, ETH Zürich, Zurich, Switzerland. Hauptthemen laut MEDLINE: Enzyme Inhibitors, Pyrazolones, Pyrazoles. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swiss National Fundation, Novartis Stiftung für Medizinisch-Biologische Forschung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In a recent study, the oxadiazin‐5‐one‐based compound CJ1‐34 was identified as a partial ATP synthase inhibitor, which was found to bind the F 1 region of the ATP synthase. These findings were used as a starting point for the design and synthesis of smaller heterocycles, such as pyrazolidine‐3‐ones and pyrazol‐3‐ones, as novel structural scaffolds for potential ATP synthase inhibitors. Among the newly synthesized compounds, pyrazolidin‐3‐one derivatives 9a and 10a outperformed the lead compound CJ1‐34 in vitro by inhibiting ATP hydrolytic activity and decreasing ATP levels in HT‐22 cells. Subsequent dose‐dependent studies identified compound 9a as the most promising ATP synthase inhibitor. Molecular docking revealed similar binding modes for all compounds in the F1‐binding site and the calculated docking scores aligned with the measured IC 50 values of the tested compounds. This study identified pyrazolidine‐3‐ones as promising structural scaffolds for ATP synthase inhibition, opening avenues for further biomedical applications in central nervous system diseases such as Alzheimer's and Parkinson's.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Enzyme InhibitorsPyrazolonesPyrazolesStructure-Activity RelationshipMolecular Docking SimulationHumansDose-Response Relationship, DrugMolecular StructureAdenosine TriphosphateBinding SitesCell LineAnimals

Stichwörter der Autor:innen

ATP synthasein vitro evaluationmolecular dockingpyrazolidin‐3‐onespyrazol‐3‐ones

Substanzen

Enzyme InhibitorsPyrazolonesAdenosine TriphosphatePyrazolespyrazolidine

Autor:innen und Institutionen

  • Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, ETH Zürich, Zurich, Switzerland.

ORCID-Profile: Amy E Fraley

Förderung

  • Swiss National Fundation
  • Novartis Stiftung für Medizinisch-Biologische Forschung

Zitieren

APA

Reichert, L., Delparente, A., Hipfinger, I. R., Reininger, L., Castro, A. P., Hubin, D. J., Schibli, R., Fraley, A. E., & Mu, L. (2026). Identification of Pyrazolidine‐3‐One Derivatives as a Novel Structural Scaffold for ATP Synthase Inhibitors. ChemMedChem, 21(14). https://doi.org/10.1002/cmdc.70399

Vancouver

Reichert L, Delparente A, Hipfinger IR, Reininger L, Castro AP, Hubin DJ, et al. Identification of Pyrazolidine‐3‐One Derivatives as a Novel Structural Scaffold for ATP Synthase Inhibitors. ChemMedChem. 2026;21(14). doi:10.1002/cmdc.70399

BibTeX
@article{Reichert2026,
  author = {Reichert, Lisa and Delparente, Aro and Hipfinger, Ida R and Reininger, Lukas and Castro, Ana Pinto and Hubin, Daniel J and Schibli, Roger and Fraley, Amy E and Mu, Linjing},
  title = {Identification of Pyrazolidine‐3‐One Derivatives as a Novel Structural Scaffold for ATP Synthase Inhibitors},
  journal = {ChemMedChem},
  year = {2026},
  volume = {21},
  number = {14},
  doi = {10.1002/cmdc.70399}
}
Kostenlos starten →